MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie Acquires 19,665 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie acquired 19,665 shares of MAIA Biotechnology stock in a transaction dated Thursday, April 25th. The stock was acquired at an average cost of $2.03 per share, with a total value of $39,919.95. Following the completion of the transaction, the director now directly owns 1,167,189 shares of the company’s stock, valued at approximately $2,369,393.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA opened at $2.94 on Friday. MAIA Biotechnology, Inc. has a 52-week low of $0.82 and a 52-week high of $3.07.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Thursday, March 21st. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Research analysts predict that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.